Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent

Open access
Dennis, Mark S., Jin, Hongkui, Dugger, Debra, Yang, Renhui, McFarland, Leanne, Ogasawara, Annie, Williams, Simon, Cole, Mary J., Ross, Sarajane, Schwall, Ralph·2007·Cancer Research

Abstract

Association with albumin as a means to improve biodistribution and tumor deposition of a Fab was investigated using AB.Fab4D5, a bifunctional molecule derived from trastuzumab (HERCEPTIN) capable of binding albumin and tumor antigen HER2 (erbB2) simultaneously. AB.Fab4D5 was compared with trastuzumab and a trastuzumab-derived Fab (Fab4D5) for the ability to target tumors overexpressing HER2 in mouse mammary tumor virus/HER2 allograft models. Biodistribution was monitored using intravital microscopy, histology, and integrated single-photon emission computed tomography/computed tomography analysis. Fab4D5 tumor deposition was characterized by rapid but transient appearance in tumor at 2 h with little retention, followed by rapid accumulation in kidney by 6 h. Trastuzumab was slow to accumulate in tumors and slow to clear from normal tissues, although significant tumor deposition was achieved by 24 h. In contrast, AB.Fab4D5 was observed at 2 h in tumor and its presence was sustained beyond 24 h similar to trastuzumab. Intravital microscopy revealed that at peak tumor accumulation, tumor cell staining by AB.Fab4D5 was more uniform than for Fab4D5 or trastuzumab. Similar tumor deposition was achieved for both AB.Fab4D5 and trastuzumab at 48 h (35.9 ± 1.8% and 38.2 ± 3.1% injected dose/g); however, AB.Fab4D5 targeted tumors more rapidly and quickly cleared from blood, leading to a lower overall normal tissue exposure. Importantly, unlike Fab4D5, AB.Fab4D5 did not accumulate in kidney, suggesting that association with albumin leads to an altered route of clearance and metabolism. Rapid targeting, excellent tumor deposition and retention, coupled with high tumor to blood ratios may make AB.Fab an exceptional molecule for imaging and cancer therapy. [Cancer Res 2007;67(1):254–61]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-2531

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Dennis, M. S., Jin, H., Dugger, D., Yang, R., McFarland, L., Ogasawara, A., Williams, S., Cole, M. J., Ross, S., & Schwall, R.
Venue
Cancer Research
Published
2007-01-01
Volume
67
Issue
1
Pages
254-261
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2162841866
Cited by
251
References
3
FWCI
12.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-2531
The paper
Dennis, M. S., Jin, H., Dugger, D., Yang, R., McFarland, L., Ogasawara, A., Williams, S., Cole, M. J., Ross, S., & Schwall, R. (2007). Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-2531

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.